Does RUXOLITINIB Cause Neoplasm malignant? 216 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 216 reports of Neoplasm malignant have been filed in association with RUXOLITINIB (OPZELURA). This represents 0.3% of all adverse event reports for RUXOLITINIB.
216
Reports of Neoplasm malignant with RUXOLITINIB
0.3%
of all RUXOLITINIB reports
52
Deaths
64
Hospitalizations
How Dangerous Is Neoplasm malignant From RUXOLITINIB?
Of the 216 reports, 52 (24.1%) resulted in death, 64 (29.6%) required hospitalization, and 8 (3.7%) were considered life-threatening.
Is Neoplasm malignant Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for RUXOLITINIB. However, 216 reports have been filed with the FAERS database.
What Other Side Effects Does RUXOLITINIB Cause?
Off label use (12,492)
Death (6,561)
Fatigue (5,663)
Anaemia (3,593)
Haemoglobin decreased (3,297)
Platelet count decreased (3,028)
Diarrhoea (2,531)
Asthenia (2,529)
Dizziness (2,398)
Pneumonia (2,343)
What Other Drugs Cause Neoplasm malignant?
RANITIDINE (10,648)
ADALIMUMAB (2,028)
APIXABAN (1,772)
ETANERCEPT (1,616)
METHOTREXATE (1,041)
TOFACITINIB (1,020)
RITUXIMAB (929)
INFLIXIMAB (892)
ABATACEPT (727)
RISANKIZUMAB-RZAA (715)
Which RUXOLITINIB Alternatives Have Lower Neoplasm malignant Risk?
RUXOLITINIB vs SABRIL
RUXOLITINIB vs SACCHAROMYCES CEREVISIAE
RUXOLITINIB vs SACITUZUMAB GOVITECAN
RUXOLITINIB vs SACITUZUMAB GOVITECAN-HZIY
RUXOLITINIB vs SACROSIDASE